



June 6, 2024

Company Name: AnGes Inc.

Presentative: Ei Yamada, President & CEO

Notice Concerning Supply Agreement for "Zokinvy"

AnGes announced on May 8, 2024 that Sentynl Therapeutics, Inc. ("Sentynl"), a US biopharmaceutical company, had been designated as the assignee of Eiger BioPharmaceuticals, Inc.'s ("Eiger") Zokinvy business ("Zokinvy Business") pursuant to an agreement by and between Eiger and Sentynl. The assignment from Eiger to Sentynl of Zokinvy Business and its related agreements that Anges Inc. had concluded with Eiger, has now been completed.

As a result, the supplier of products sold in Japan in connection with the Zokinvy Business will change from Eiger to Sentynl, but we expect no other changes to the Zokinvy Business at this time, including future product supplies.

This event will not have any impact on our consolidated financial results for the current fiscal year.

(Note) This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.